Singh Biotechnology: Unlocking the “Undruggable”
Dr. Sunanda Singh, M.D., Ph.D., Founder
Singh Biotechnology is replacing this high-stakes balancing act with a clear path to safer, more precise therapies.
Founded by Dr. Sunanda Singh, M.D., Ph.D., the company has developed a proprietary class of cell-penetrating nano-antibodies that are capable of entering the cell and acting directly on intracellular proteins, offering a potential solution to diseases previously labeled ‘undruggable.’
“Our nano-antibodies are about one-tenth the size of conventional antibodies and can unlock high-value intracellular targets across cancer, autoimmune and ophthalmic diseases where existing therapies have failed or stalled,” says Dr. Singh.
At the core of Singh Biotechnology’s work is SBT-100, a proprietary nano-antibody demonstrating potent effects in several aggressive cancers, including triple-negative breast cancer, pancreatic cancer, bone cancer, and leukemia. It targets two key intracellular proteins — KRAS and STAT3 — that play critical roles in cancer progression and immune dysfunction.
Data from collaborations with the National Institutes of Health, Emory Medical School, and the University of Florida confirm that SBT-100 can meaningfully alter disease progression in multiple cancer models. The antibody’s potential has been acknowledged by the FDA through an orphan drug designation for pancreatic cancer and osteosarcoma, along with a favorable response to a pre-IND submission for its breast cancer program.
SBT-100 also shows strong therapeutic potential in autoimmune and ophthalmic diseases. In autoimmune conditions like multiple sclerosis, Sjögren’s syndrome, and autoimmune uveitis, SBT-100 appears to restore immune balance by blocking hyperactive STAT3 signaling in T cells—a common pathological feature across many such disorders. Because many autoimmune conditions are driven by overlapping immune pathways, these nano-antibodies hold strong promise to transform how such diseases are treated.
In collaboration with the veterinary school at the University of Florida, the company demonstrated that SBT-100, delivered as an eye drop, could reach all layers of the eye, including the retina.
By targeting VEGF, a protein that causes abnormal blood vessel growth, it could potentially replace painful eye injections currently used to treat conditions like macular degeneration and diabetic retinopathy, both leading causes of blindness globally. Current treatments require patients to receive needle injections directly into the eye, often monthly, which deters adherence and limits access. A topical therapy based on SBT-100 could radically change how these chronic conditions are managed.
While SBT-100 leads the pipeline, Singh Biotechnology has developed three additional nano-antibodies:
SBT-101: Targets STAT3
SBT-102: Targets KRAS
SBT-104: Targets TNF-alpha
SBT-100 also shows strong therapeutic potential in autoimmune and ophthalmic diseases. In autoimmune conditions like multiple sclerosis, Sjögren’s syndrome, and autoimmune uveitis, SBT-100 appears to restore immune balance by blocking hyperactive STAT3 signaling in T cells—a common pathological feature across many such disorders. Because many autoimmune conditions are driven by overlapping immune pathways, these nano-antibodies hold strong promise to transform how such diseases are treated.
In collaboration with the veterinary school at the University of Florida, the company demonstrated that SBT-100, delivered as an eye drop, could reach all layers of the eye, including the retina.
By targeting VEGF, a protein that causes abnormal blood vessel growth, it could potentially replace painful eye injections currently used to treat conditions like macular degeneration and diabetic retinopathy, both leading causes of blindness globally. Current treatments require patients to receive needle injections directly into the eye, often monthly, which deters adherence and limits access. A topical therapy based on SBT-100 could radically change how these chronic conditions are managed.
While SBT-100 leads the pipeline, Singh Biotechnology has developed three additional nano-antibodies:
SBT-101: Targets STAT3
SBT-102: Targets KRAS
SBT-104: Targets TNF-alpha
These next-generation therapies build on the same nano-antibody platform and are aimed at tackling a broader set of diseases.
With 118 issued patents across major global markets, including the U.S., Europe, China, Japan, and India, the company’s platform is entirely proprietary, offering both strong IP protection and freedom to operate.
Now entering a critical inflection point, Singh Biotechnology is seeking to raise capital to launch its first-in-human oncology trial and advance ophthalmic studies, particularly for autoimmune uveitis. As partnerships with leading institutions and biotech players take shape, the coming 18 to 24 months will be pivotal in bringing Singh Biotechnology’s vision to life. For investors, this next chapter presents an opportunity to fuel a pipeline-in-a-drug that could redefine standards in oncology and immune-driven disease.
With SBT-100, Singh Biotechnology is advancing a first-in-class approach to some of the most difficult and high-need areas in medicine, laying the groundwork for a new era of intracellular immunotherapy.
Behind the company’s cutting-edge science is a streamlined engine driving progress with remarkable efficiency. Functioning virtually since inception, Singh Biotechnology has built a capital-efficient research engine through collaborations with premier U.S. institutions such as the National Institutes of Health, Emory Medical School, the University at Buffalo, Illinois Institute of Technology, and the University of Florida. This lean model has allowed it to generate robust data without the overhead of traditional lab infrastructure.Our nano-antibodies are about one-tenth the size of conventional antibodies and can unlock high-value intracellular targets across cancer, autoimmune and ophthalmic diseases where existing therapies have failed or stalled
With 118 issued patents across major global markets, including the U.S., Europe, China, Japan, and India, the company’s platform is entirely proprietary, offering both strong IP protection and freedom to operate.
Now entering a critical inflection point, Singh Biotechnology is seeking to raise capital to launch its first-in-human oncology trial and advance ophthalmic studies, particularly for autoimmune uveitis. As partnerships with leading institutions and biotech players take shape, the coming 18 to 24 months will be pivotal in bringing Singh Biotechnology’s vision to life. For investors, this next chapter presents an opportunity to fuel a pipeline-in-a-drug that could redefine standards in oncology and immune-driven disease.
With SBT-100, Singh Biotechnology is advancing a first-in-class approach to some of the most difficult and high-need areas in medicine, laying the groundwork for a new era of intracellular immunotherapy.
